Ftse Mib
34.657,35
0,93%
DAX
18.772,85
0,50%
S&P 500
5.222,68
0,16%
NASDAQ
16.340,87
-0,03%
Bitcoin
60.857,02
0,10%

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Acer Therapeutics Inc (ACER) Acer Therapeutics Inc (ACER) Notizie

ACER

Acer Therapeutics (ACER)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:ACER
DataOraFonteTitoloSimboloCompagnia
08/11/202322:13Edgar (US Regulatory)Form 425 - Prospectuses and communications, business combinationsNASDAQ:ACERAcer Therapeutics Inc
08/11/202322:11Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ACERAcer Therapeutics Inc
02/11/202313:51Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:ACERAcer Therapeutics Inc
02/11/202313:30GlobeNewswire Inc.Leading Independent Proxy Advisory Firms ISS and Glass Lewis Recommend Acer Therapeutics Shareholders Vote "FOR" the Proposed Merger and Related ProposalsNASDAQ:ACERAcer Therapeutics Inc
10/10/202323:17Edgar (US Regulatory)Form DEFM14A - Definitive proxy statement relating to merger or acquisitionNASDAQ:ACERAcer Therapeutics Inc
31/08/202313:30GlobeNewswire Inc.Zevra Therapeutics to Acquire Acer Therapeutics, Expanding its Rare Disease Portfolio and Adding Commercial ProductNASDAQ:ACERAcer Therapeutics Inc
30/08/202322:05GlobeNewswire Inc.Acer Therapeutics Reacquires Worldwide Development, Commercialization and Economic Rights to OLPRUVA™ from Relief Therapeutics, Excluding the Geographical EuropeNASDAQ:ACERAcer Therapeutics Inc
14/08/202322:19Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ACERAcer Therapeutics Inc
14/08/202322:05GlobeNewswire Inc.Acer Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate UpdateNASDAQ:ACERAcer Therapeutics Inc
26/06/202315:01Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:ACERAcer Therapeutics Inc
26/06/202314:30GlobeNewswire Inc.Acer Therapeutics Receives $1 Million Capital Infusion from Chief Executive Officer and FounderNASDAQ:ACERAcer Therapeutics Inc
15/05/202323:29Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:ACERAcer Therapeutics Inc
15/05/202323:10GlobeNewswire Inc.Acer Therapeutics Reports Q1 2023 Financial Results and Provides Corporate UpdateNASDAQ:ACERAcer Therapeutics Inc
01/05/202314:30GlobeNewswire Inc.Acer Therapeutics Announces OLPRUVA™ Commercial Launch Progressing Ahead of ScheduleNASDAQ:ACERAcer Therapeutics Inc
27/04/202312:25Edgar (US Regulatory)Prospectus Filed Pursuant to Rule 424(b)(2) (424b2)NASDAQ:ACERAcer Therapeutics Inc
14/04/202322:29Edgar (US Regulatory)Annual Report to Security Holders (ars)NASDAQ:ACERAcer Therapeutics Inc
27/03/202322:18Edgar (US Regulatory)Securities Registration: Employee Benefit Plan (s-8)NASDAQ:ACERAcer Therapeutics Inc
27/03/202322:13Edgar (US Regulatory)Annual Report (10-k)NASDAQ:ACERAcer Therapeutics Inc
27/03/202322:01GlobeNewswire Inc.Acer Therapeutics Reports Q4 and Full Year 2022 Financial Results and Provides Corporate UpdateNASDAQ:ACERAcer Therapeutics Inc
23/03/202321:17Edgar (US Regulatory)Prospectus Filed Pursuant to Rule 424(b)(5) (424b5)NASDAQ:ACERAcer Therapeutics Inc
22/03/202313:30GlobeNewswire Inc.Acer Therapeutics Announces Data Presented at Society for Inherited Metabolic Disorders Annual Meeting Identifying Preferred Urea Cycle Disorder Treatment AttributesNASDAQ:ACERAcer Therapeutics Inc
22/03/202313:00GlobeNewswire Inc.Acer Therapeutics Announces $2.675 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesNASDAQ:ACERAcer Therapeutics Inc
17/03/202313:30GlobeNewswire Inc.Acer Therapeutics Announces Topline Results from ACER-801 (Osanetant) Phase 2a TrialNASDAQ:ACERAcer Therapeutics Inc
16/03/202321:51Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:ACERAcer Therapeutics Inc
15/03/202313:30GlobeNewswire Inc.Acer Therapeutics Announces Presentation of HCP Urea Cycle Disorder Treatment Preference Data at the Society for Inherited Metabolic Disorders Annual Meeting and Provides OLPRUVA™ Program UpdateNASDAQ:ACERAcer Therapeutics Inc
14/02/202323:17Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:ACERAcer Therapeutics Inc
13/02/202314:30GlobeNewswire Inc.Acer Therapeutics Announces Full Enrollment of Phase 2a Trial of ACER-801 (Osanetant) for Treatment of Moderate to Severe Vasomotor Symptoms Associated with MenopauseNASDAQ:ACERAcer Therapeutics Inc
31/01/202314:00PR Newswire (US)SWK Holdings Provides Portfolio Update Highlighting Recent AchievementsNASDAQ:ACERAcer Therapeutics Inc
09/01/202314:30GlobeNewswire Inc.Acer Therapeutics Highlights Key 2022 Achievements and Pipeline Advancements, and Provides Anticipated 2023 MilestonesNASDAQ:ACERAcer Therapeutics Inc
05/01/202314:30GlobeNewswire Inc.Acer Therapeutics Announces Initiation of Two Investigator-Sponsored Trials of ACER-801 (Osanetant) in Men with Adenocarcinoma of the ProstateNASDAQ:ACERAcer Therapeutics Inc
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:ACER

La tua Cronologia

ASX
TLSSWY
EU
ALHOP
Hopscotch Groupe
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' CLICCA QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network